β3-agonist therapy: a new advance in the management of overactive bladder?
Christopher R
CR
Chapple
D058667:Adrenergic beta-3 Receptor Agonists / Q000627:therapeutic use*; D000814:Aniline Compounds / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D001743:Urinary Bladder / Q000187:drug effects*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D014549:Urinary Incontinence / Q000188:drug therapy*
D058667:Adrenergic beta-3 Receptor Agonists; D000814:Aniline Compounds; D001565:Benzoates; D001713:Biphenyl Compounds; C523977:solabegron